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Abstract
Background Although studies have shown that EUS has a
high sensitivity and specificity for T and N staging, the
value of EUS for staging tumors as resectable or nonre-
sectable after CT of the chest and abdomen and US neck
assessment, is largely unknown. This study was designed
to assess the diagnostic value of EUS for determining
resectability of esophageal cancer.
Methods A retrospective analysis of all consecutive
patients with esophageal carcinoma who underwent staging
EUS, CT, and US. Tumors were considered resectable
when there was no evidence of metastases or ingrowth in
adjacent structures. Sensitivity, specificity, positive (PPV),
and negative (NPV) predictive value of CT/US neck and
CT/US neck ? EUS for predicting surgical resectability
were calculated. PPVs of CT/US alone and CT/US ? EUS
together were compared for assessing the diagnostic value
of EUS.
Results In total, 211 patients (155 men; mean age of
64 ± 9.4 years) were included, of which 176 (83 %)
underwent all three staging investigations. Based on preop-
erative staging, 173 (82 %) patients were considered
resectable and 38 (18 %) nonresectable. Of all 173 initially
resectable patients, 145 were operated on. Of these patients,
five (3.4 %) tumors were found nonresectable during sur-
gery. Postoperative sensitivity, specificity, PPV, and NPV of
CT/US and CT/US ? EUS for predicting surgical resect-
ability were 88 versus 87 %, 20 versus 40 %, 97 versus
98 %, and 6 versus 10 %, respectively.
Conclusions Although EUS adds to the specificity of
preoperative esophageal cancer staging after CT chest and
abdomen, and US of the neck have been performed, the
overall added value of EUS is limited.
Keywords Esophageal cancer  Endoscopic
ultrasonography  Surgical resectability
Approximately 50 % of patients with esophageal cancer
present with potentially resectable disease [1]. Current
guidelines recommend computed tomography (CT) of the
chest and abdomen, ultrasonography (US) of the neck, and
endoscopic ultrasonography (EUS) for staging of esopha-
geal cancer [2–4]. Although CT of the chest and abdomen
and US of the neck are primarily used for the detection of
distant metastases, EUS provides information on local
resectability (T stage) and locoregional lymphadenopathy
(N stage) [5, 6].
One of the main goals of esophageal cancer staging is to
select patients who are suitable for surgical resection of the
tumor, because surgery remains the best curative option for
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patients without distant metastases or tumor ingrowth in
adjacent structures outside the diaphragm or pleura.
Although recent meta-analyses have shown that EUS has a
high sensitivity (75–84 %) and specificity (65–75 %) for T
and N staging [5, 6], the impact of EUS findings for final
surgical decision making (resectable or nonresectable) after
CT chest and abdomen and US neck have been performed,
is largely unknown. Moreover, well-designed comparative
impact studies are not available and published data on this
topic are conflicting [7, 8]. Other drawbacks of EUS
include its invasive character and the risk of esophageal
perforation during the procedure [9].
The goal of this study was to evaluate the diagnostic
value of staging EUS for determining surgical resectability
of esophageal cancer after CT chest and abdomen and US
neck have been performed and how often the outcome of
staging EUS would have changed the therapeutic man-
agement of these patients.
Patients and methods
All consecutive patients with biopsy-proven esophageal
cancer who underwent staging EUS between June 2006 and
May 2010 at the Department of Gastroenterology and
Hepatology of the University Medical Center Utrecht, the
Netherlands, a tertiary referral center for treatment of
esophageal cancer, were included. The patient search was
performed in the electronic endoscopy report system
Endoalpha Documentation (Olympus, Hamburg, Germany)
using the key words ‘‘EUS’’ and ‘‘staging esophageal/
gastric cardia cancer.’’ All patients underwent a standard-
ized preoperative staging protocol, consisting of a CT chest
and abdomen, US neck, and EUS esophagus and upper
abdomen. All data were collected from the medical charts.
Staging investigations
CT chest and abdomen
A 16- or 64-multidetector row spiral CT scanner (Philips MX
8000 IDT and Philips Brilliance, respectively; Philips
Medical Systems, Best, The Netherlands or Somatom Sen-
sation; Siemens Medical Systems, Erlangen, Germany) was
used. Thoracic and upper abdomen CT scans were performed
after oral contrast intake and intravenous contrast injection,
using a detector configuration of 16 mm or 64 9 0.75 mm,
120 kVp, individualized mAs, a tube rotation time of 0.5 s,
and a pitch of 1.3. Overlapping transverse sections were
reconstructed using a slice thickness of 5 mm at 4-mm
increments. CT images were evaluated for the presence of
the primary tumor, invasion into adjacent structures, pres-
ence of locoregional lymph nodes (N0-1), and distant organ
metastases (M0-1), according TNM-classification version 6.
Tumors were judged as T4 stage or tumor stage less than T4.
Lymph nodes measuring 10 mm or more were considered
tumor positive. For patients who underwent multiple CT
scans, the latest scan was included in the analysis because the
final decision on resectability was based on this scan.
US neck
Cervical lymph nodes with a diameter of 6 mm or more
were considered to be potentially malignant and sub-
sequent fine needle aspiration (FNA) was performed. In
addition, lymph nodes were punctured for FNA if their
structure or shape was suggestive of malignancy, i.e.,
round, hypoechoic with sharp margins. The FNA result was
defined as positive if cytology confirmed malignancy and
negative if no suspected lymph nodes were reported on US
or if FNA did not yield malignant cells.
EUS
All EUS examinations were performed by a single endos-
copist (FV), who has performed [350 EUS procedures
over the years, using a radial scanning echoendoscope (GF-
UM130 or GF-UE160, Olympus, Hamburg, Germany).
Patients received sedation with midazolam and pethidine or
fentanyl. Tumors were staged (TNM) according to the 6th
edition of the UICC, which was used in the study period
[10]. Dilation of the tumor was not performed if the
echoendoscope could not pass the tumor.
Management after tumor staging
When CT, US, and EUS in a patient with esophageal cancer
had been performed, resectability of the tumor was discussed
in the multidisciplinary gastrointestinal oncology team,
consisting of a surgeon, radiologist, radiotherapist, pathol-
ogist, medical oncologist, and gastroenterologist. Additional
examinations, such as PET, MRI, or bronchoscopy, were
only performed when there was doubt of resectability based
on the outcomes of CT, US, and/or EUS. If no evidence of
distant metastases or invasion into adjacent organs was
found except for ingrowth in the pleura or diaphragm, tumors
were considered resectable. Patients who were fit to undergo
surgery underwent esophagectomy with or without neoad-
juvant treatment (initial chemotherapy for adenocarcinoma
alone, later chemoradiation for squamous cell carcinoma,
and chemotherapy for adenocarcinoma). Preoperative,
nonresectable disease was defined as the composite of either
(1) proven metastases by biopsy or mortality within
6 months after diagnosis due to progressive tumor growth,
or (2) nonresectability of the tumor as proven by other
investigations, such as PET, MRI, or bronchoscopy.
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Postoperatively, nonresectable disease was defined as non-
resectability during surgery.
Statistical analysis
Accuracy of thoracic/upper abdominal CT ? US neck with
or without EUS for predicting surgical resectability were
compared to assess the additional value of EUS, by cal-
culating sensitivity, specificity, and positive (PPV) and
negative (NPV) predictive value for surgical resectability.
This comparison was made preoperatively as well as
postoperatively. Preoperatively, the ‘‘gold standard’’ for
determining resectability was based on all preoperative
staging tests. Postoperatively, the resection itself was the
‘‘gold standard.’’ All analyses were performed by using the
SPSS version 15.0 (SPSS Inc., Chicago, IL).
Results
Of the 231 patients who underwent staging EUS, 20
patients were excluded because EUS was the only inves-
tigation that had been performed (Fig. 1). This resulted in
211 patients (155 men; mean age of 64 ± 9.4 years) that
were included. Patient and tumor characteristics are shown
in Table 1. Two EUS reports did not provide data on
location of the tumor.
Of the 211 patients, 176 (83 %) underwent all three
standard staging investigations. EUS was incomplete in 17
patients due to the presence of a tumor that was stenotic,
preventing passage of the echoendoscope. US neck was
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missing in 18 patients. In 81 patients, one or more addi-
tional investigations were performed, i.e., PET scan
(32 %), abdominal ultrasound (25 %), MRI liver (13 %),
or bronchoscopy (13 %). Staging results of EUS, CT, and
US neck are shown in Tables 2, 3, and 4. In Tables 5 and 6,
the accuracy of EUS for T and N staging of patients who
did not undergo neoadjuvant therapy is shown, using the
pathologic specimen as the ‘‘gold standard.’’
Based on preoperative staging, esophageal cancers were
in 173 patients (82 %) considered to be resectable and in 38
(18 %) nonresectable. Of the latter, 17 patients had biopsy-
proven metastases (lymph node, n = 10; kidney, n = 1;
liver, n = 1; bone, n = 2; ascites, n = 2; pleural fluid,
n = 1), 9 had tumor progression during neoadjuvant ther-
apy, 2 had biopsy-proven tracheal/bronchial ingrowth, and
10 had convincing evidence of ingrowth or metastases as
shown by other investigations (CT, n = 1; EUS, n = 1; EUS
and CT, n = 3; CT and PET, n = 1; EUS and US neck,
n = 1, MRI and PET liver, n = 1, MRI liver, n = 1; MRI
brain, n = 1). Preoperative sensitivity, specificity, PPV and
NPV of CT/US, and CT/US ? EUS for predicting surgical
resectability were 88 versus 87 %, 76 versus 87 %, 94 versus
97 %, and 58 versus 59 %, respectively (Table 7).
Of all 173 patients who were considered to be resectable
after preoperative staging, 145 (84 %) underwent surgery.
In 14 patients another treatment modality was performed
(endoscopic mucosal resection or definitive chemoradia-
tion), 5 patients refused surgery, 7 were not operable due to
severe comorbidity, and 2 had other reasons. Of the 145
operated patients, 69 patients (49 %) had received neoad-
juvant therapy before surgery.
Five (3.4 %) patients were found to have a nonresec-
table tumor during surgery. Three of them had ingrowth in
adjacent structures (pulmonary vein and right main bron-
chus, n = 1; right main bronchus, n = 1; aorta and celiac
trunk, n = 1) and two patients had metastases that had not
been detected during preoperative staging (liver metastasis,
n = 1; retroperitoneal metastasis, n = 1). In two of these
patients, complete EUS had not been performed because
the tumor was too stenotic and passage of the echoendo-
scope was not possible. Two of these five patients had
received neoadjuvant chemotherapy. Postoperative sensi-
tivities, specificities, PPVs, and NPVs of CT/US and CT/
US ? EUS for predicting surgical resectability were 88
versus 87 %, 20 versus 40 %, 97 versus 98 %, and 6 versus
10 %, respectively (Table 8).
Table 2 TNM stage based on EUS findings
N % N % N %
T1 30 16 N0 69 36 Mx 151 78
T2 13 7 N1 123 64 M0 13 7
T3 125 65 Total 192 100 M1
T4 23 M1a 24 12
T4a 9 5 M1b 6 3
T4b 14 7 Total 194 100
Total 191 100
Missing 20 Missing 19 Missing 17
Table 3 TNM stage based on CT findings
N % N % N %
T \ 4 196 93 N0 108 51 cM0 177 84
T4a 3 1 N1 103 49 cM1 33 15
T4b 12 6 pM1 1 1
Total 211 100 Total 211 100 Total 211 100







Table 5 Accuracy of EUS for tumor (T) depth staging of patients without neoadjuvant therapy
EUS T stage Pathologic T stage
T1 T2 T3 T4 T0 Tis Total % correct
T1 14 0 0 0 0 1 15 93
T2 3 1 0 0 0 0 4 25
T3 1 2 37 2 0 0 42 88
T4 0 0 3 4 0 0 7 57
Total 18 3 40 6 0 1 68 84
Overstaged 22 % 67 % 8 %
Understaged 33 %
The number of cases in which EUS and pathology results were equal are depicted in bold
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Discussion
In this study, we show that the diagnostic value of staging
EUS for determining surgical resectability when staging
with thoracic/abdominal CT and US neck performed in the
setting of our institution was limited. The PPV for deter-
mining resectability increased nonsignificantly from 97 to
98 %; in other words, only in 1 of 100 cases the addition of
EUS to thoracic and abdominal CT and US neck resulted in
a clinically significant result, i.e., a surgical resection was
not performed. The specificity for determining nonresec-
tability increased from 20 to 40 % by adding EUS; how-
ever, this outcome is based on data of only 5 of 211
patients (Table 8).
Avoiding unnecessary surgery for nonresectable esoph-
ageal cancer is one of the main objectives of preoperative
staging with EUS. It is widely accepted that EUS has the
highest accuracy for T and N staging of esophageal cancer
[5]. EUS is regarded as superior to CT in this regard and is
thought to be more accurate for evaluation of resectability
[11–15]. However, randomized trials comparing the clini-
cal impact of staging protocols with and without EUS have
not been performed. A recently published prospective
cohort study also showed that EUS was insensitive with
respect to resectability and the authors concluded that it
should not be performed upfront in every patient [16].
Furthermore, the impact of a diagnostic finding of EUS on
treatment policy often depends on the locally used treat-
ment protocol [2]. In the Netherlands, the vast majority
of esophageal cancer patients who are staged T2-3N0-
1M0-1a (UICC edition 6) are treated by neoadjuvant
chemo(radio)therapy followed by esophagectomy. Because
patients with a T2N0M0 tumor are treated similarly as
patients with a T3N1M1a tumor, the impact on treatment
of differentiating between T2 or T3 tumors by EUS is very
low or even absent. Moreover, it has recently been shown
that EUS in T1 lesions has a low accuracy for distin-
guishing submucosal (T1sm) from mucosal cancer (T1m).
Recently, Pouw et al. [17] reported that EUS had virtually
no clinical impact on the workup of early esophageal
neoplasia (T1N0). A diagnostic endoscopic mucosal
resection (EMR), which may be therapeutic if the lesion is
confined to the mucosal layer is the preferred intervention
for staging of these early lesions. Finally, only 14 of 211
tumors (6.6 %) were considered nonresectable on EUS
because they were staged as T4b (UICC TNM 7th edition).
Based on this, we recommend performing thoracic/
abdominal CT and US neck upfront, followed by EUS if its
result may affect further treatment, i.e., as despite the result
of CT doubt on resectability remains (Fig. 2).
Our study focused on the additional value of EUS for
determining surgical resectability. However, EUS also is
able to address other clinical endpoints, such as pretreat-
ment TNM stage, overall clinical management, and sur-
vival, which may be important factor for predicting a
patient’s prognosis. A reduced survival has been shown to
be associated with higher numbers of affected lymph
nodes, a factor that has now been incorporated in the
Table 6 Accuracy of EUS for lymph node (N) staging of patients
without neoadjuvant therapy
EUS Pathological stage
N0 N1 Total % correct
N0 14 12 26 64
N1 6 37 43 86
Total 20 49 69 74
Overstaged 30 %
Understaged 25 %
The number of cases in which EUS and pathology results were equal
are depicted in bold
Table 7 Preoperative sensitivity, specificity, PPV, and NPV of
CT ? US and CT ? US ? EUS for predicting surgical resectability
Resectable Nonresectable Total
CT ? US
Resectable 152 9 161
Nonresectable 21 29 50
CT ? US ? EUS
Resectable 150 5 155
Nonresectable 23 33 56
Total 173 38 211




CT ? US 94 58 88 76
CT ? US ? EUS 97 59 87 87
Table 8 Postoperative sensitivity, specificity, PPV, and NPV of
CT ? US and CT ? US ? EUS for predicting surgical resectability
Resectable Nonresectable Total
CT ? US
Resectable 123 4 127
Nonresectable 17 1 18
CT ? US ? EUS
Resectable 122 3 125
Nonresectable 18 2 20









CT ? US 97 6 88 20
CT ? US ? EUS 98 10 87 40
2832 Surg Endosc (2012) 26:2828–2834
123
newest version (7th) of the TNM-classification [18].
Moreover, the surgical approach for esophagectomy, i.e.,
transhiatal or transthoracic, may depend on the presence
and determination of the exact location of malignant lymph
nodes. Malignant mediastinal lymph nodes located along
the distal esophagus can be resected effectively via the
transhiatal route. In contrast, malignant supracranial nodes
should be removed by a transthoracic approach. EUS,
combined with FNA for cytology, has a high accuracy for
determining the benign or malignant nature of a lymph
node [5, 19, 20], even in low-volume EUS centers [21].
However, the strongest prognostic factor and determinant
for a therapeutic option remains the presence of distant
metastases, for which CT thorax and abdomen and US neck
are the most reliable techniques for detection.
The choice for a transhiatal or transthoracic surgical
approach not only depends on nodal involvement, but also is
determined by tumor location, i.e., the Siewert classification
[22]. The Dutch esophageal cancer guideline recommends
performing a radical transthoracic resection with abdominal
and mediastinal lymph node dissection in case of Siewert
type-I tumors (adenocarcinoma of the distal esophagus).
Transhiatal esophagectomy with resection of distal perie-
sophageal and peri-truncal nodes and nodes along the left
gastric artery is advised in patients with Siewert type II–III
tumors (cardia carcinoma-subcardiac gastric cancer). Total
gastrectomy instead of esophagectomy may be an alternative
surgical approach to Siewert type II–III tumors [2]. EUS
combined with endoscopy may assist in determining the
Siewert classification, although data on this are scarce [23].
Pedrazzani et al. [23] showed that the sensitivity and speci-
ficity for preoperative staging of Siewert type I cancers with a
combination of endoscopy and EUS were 90 and 82 %,
respectively, whereas these scores decreased to 75 and 69 %,
respectively, when only endoscopy was performed. Distin-
guishing type II from type III lesions seemed even more
difficult with sensitivities well below 75 %. However, the
number of patients included in this study was relatively small,
therefore, these data should be interpreted with caution.
A potential limitation of our study may be its retrospective
design, but because all consecutive patients in a given time
interval were included, no bias in patient selection occurred.
Another drawback may be the nature of our institution, which
is a referral center for the surgical and endoscopic treatment of
esophageal cancer. In the majority of patients, the staging
workup, mostly US neck and abdominal/thoracic CT, had
already been performed in the referring hospital. Most patients
who are undergoing staging EUS in our clinic have been
referred for surgery or EMR, consequently patients with
metastasized or overtly nonresectable disease are rarely seen
for EUS. In our opinion, this unlikely reduces the strength of
our findings. In contrast, inclusion of the above-mentioned
patient category will even further reduce the impact of EUS on
determining surgical resectability. We deliberately did not
exclude patients in whom passage of the echoendoscope was
not possible, as this is an inherent limitation of EUS.
Conclusions
Although EUS adds to the specificity of esophageal cancer
staging after abdominal/thoracic CT and US neck have
been performed, the added value for surgical decision
making seems limited in our setting. We therefore think
that EUS should not be a standard examination in the
diagnostic workup of all patients with esophageal cancer
but rather should be performed if the outcome likely affects
further treatment. More studies are needed to determine in
detail in what subgroup of patients with esophageal cancer
EUS adds to the treatment decision.
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